Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC lifted its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 2.9% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,333,470 shares of the company’s stock after purchasing an additional 93,091 shares during the quarter. Geode Capital Management LLC owned about 2.24% of Xeris Biopharma worth $9,502,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of XERS. Barclays PLC grew its stake in Xeris Biopharma by 87.8% during the third quarter. Barclays PLC now owns 324,472 shares of the company’s stock worth $925,000 after buying an additional 151,685 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Xeris Biopharma by 11.7% during the 3rd quarter. Wellington Management Group LLP now owns 471,644 shares of the company’s stock valued at $1,344,000 after acquiring an additional 49,535 shares in the last quarter. Walleye Capital LLC purchased a new stake in Xeris Biopharma during the 3rd quarter worth $3,197,000. Quantbot Technologies LP acquired a new stake in Xeris Biopharma in the 3rd quarter valued at $44,000. Finally, Intech Investment Management LLC purchased a new position in Xeris Biopharma in the third quarter valued at about $130,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analyst Upgrades and Downgrades

XERS has been the subject of a number of recent research reports. HC Wainwright increased their target price on Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research note on Monday, November 11th. Piper Sandler downgraded shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Monday, November 11th.

Xeris Biopharma Price Performance

NASDAQ:XERS opened at $3.39 on Thursday. The firm has a 50-day moving average of $3.32 and a two-hundred day moving average of $2.85. The stock has a market cap of $505.38 million, a P/E ratio of -7.53 and a beta of 2.65. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.69 and a 1-year high of $3.87.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.